194 related articles for article (PubMed ID: 31556223)
1. The effects of topiroxostat on vascular function in patients with hyperuricemia.
Higa S; Shima D; Tomitani N; Fujimoto Y; Kario K
J Clin Hypertens (Greenwich); 2019 Nov; 21(11):1713-1720. PubMed ID: 31556223
[TBL] [Abstract][Full Text] [Related]
2. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
[TBL] [Abstract][Full Text] [Related]
3. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
[TBL] [Abstract][Full Text] [Related]
4. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
5. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T
PLoS One; 2022; 17(1):e0261445. PubMed ID: 35077456
[TBL] [Abstract][Full Text] [Related]
6. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
7. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Kario K; Nishizawa M; Kiuchi M; Kiyosue A; Tomita F; Ohtani H; Abe Y; Kuga H; Miyazaki S; Kasai T; Hongou M; Yasu T; Kuramochi J; Fukumoto Y; Hoshide S; Hisatome I
J Clin Hypertens (Greenwich); 2021 Feb; 23(2):334-344. PubMed ID: 33400348
[TBL] [Abstract][Full Text] [Related]
9. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Sezai A; Obata K; Abe K; Kanno S; Sekino H
Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
[TBL] [Abstract][Full Text] [Related]
10. Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
.
Tohyo S
Int J Clin Pharmacol Ther; 2019 Nov; 57(11):567-570. PubMed ID: 31496508
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
Ishikawa T; Maeda T; Hashimoto T; Nakagawa T; Ichikawa K; Sato Y; Kanno Y
Clin Drug Investig; 2020 Sep; 40(9):847-859. PubMed ID: 32621143
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
Hosoya T; Ishikawa T; Ogawa Y; Sakamoto R; Ohashi T
Clin Drug Investig; 2018 Dec; 38(12):1135-1143. PubMed ID: 30219951
[TBL] [Abstract][Full Text] [Related]
13. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Terawaki H; Hoshi H; Kazama JJ
Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
[No Abstract] [Full Text] [Related]
14. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
[TBL] [Abstract][Full Text] [Related]
15. Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice.
Nakamura T; Nampei M; Murase T; Satoh E; Akari S; Katoh N; Mizukami H
Nutr Diabetes; 2021 Apr; 11(1):12. PubMed ID: 33850106
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1
Ohata K; Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Katayama K; Asano J; Kimura K; Shibagaki Y
Eur J Pharmacol; 2017 Nov; 815():88-97. PubMed ID: 28888756
[TBL] [Abstract][Full Text] [Related]
17. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Mitsuboshi S; Yamada H; Nagai K; Okajima H
Biol Pharm Bull; 2017; 40(9):1463-1467. PubMed ID: 28867729
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
